The pharmacodynamics and efficacy of Implanon®

Croxatto, H; Mäkäräinen, Leo

doi:10.1016/s0010-7824(98)00118-8

Cited by 174 publications

(93 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is likely that similar effects may be seen with the etonogestrel implant, which also inhibits ovulation (36). However, other progestin-only treatments such as the LNG-IUS, which exerts its hormonal action at a local level within the uterus, rather than through inhibition of ovulation, or the lower-dose POPs, which act primarily through their effect on cervical mucus, may have not have the same effect on migraine.…”

Section: Overall Completeness and Applicability Of Evidencementioning

confidence: 98%

Effectiveness of the progestin-only pill for migraine treatment in women: A systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

Background Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coinciding with peak fertility. Hormonal contraception is often tailored for migraine prevention. Estrogen-containing contraceptives may be contraindicated in women experiencing migraine with aura due to the risk of vascular events. While improvements in migraine with a progestin-only pill (POP), which inhibits ovulation are documented, the strength and quality of evidence has not been formally evaluated. Objectives To determine the effectiveness of progestin-only contraceptives for migraine treatment by systematic review and meta-analysis. Data sources and selection MEDLINE, EMBASE and Cochrane Libraries were searched (1980 to September 2016) for studies on progestin-only treatments for migraine. Studies in English on >4 non-menopausal women aged 18-50 with migraine diagnosed by formal criteria were included. Data extraction and analysis Data were quality-assessed using the GRADE system. A random effects model was used for pooled analyses. Results Pooled analyses of four studies demonstrated that desogestrel 75 mcg/day, POP significantly but modestly reduced the number of migraine attacks and migraine days. Reduced intensity and duration, reduced analgesic and triptan use were observed, along with improved headache-related quality of life. GRADE analysis indicated evidence was low to very low for each outcome measure. Adverse effects resulted in treatment cessation for <10% of participants. Two studies compared desogestrel POP to a combined oral contraceptive, demonstrating similar migraine outcomes for both treatments. Conclusions The desogestrel POP shows promise in improving migraine in women. Current evidence is observational and based on small samples of women using only one oral progestin-only formulation. Further randomized trials on additional progestin-only contraceptives are required to confirm their role in migraine management. Abstract Background: Migraine is highly prevalent in women (18%). Peak morbidity affects their most productive years, coinciding with peak fertility. Hormonal contraception is often tailored for migraine prevention. Estrogen-containing contraceptives may be contraindicated in women experiencing migraine with aura due to the risk of vascular events. While improvements in migraine with a progestin-only pill (POP), which inhibits ovulation are documented, the strength and quality of evidence has not been formally evaluated. Objectives: To determine the effectiveness of progestin-only contraceptives for migraine treatment by systematic review and meta-analysis. Data sources and selection: MEDLINE, EMBASE and Cochrane Libraries were searched (1980 to September 2016) for studies on progestin-only treatments for migraine. Studies in English on >4 non-menopausal women aged 18-50 with migraine diagnosed by formal criteria were included. Data extraction and analysis: Data were quality-assessed using the GRADE system. A random effects model was used for pooled analyses. R...

show abstract

Section: Overall Completeness and Applicability Of Evidencementioning

confidence: 98%

Effectiveness of the progestin-only pill for migraine treatment in women: A systematic review and meta-analysis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Implanon consists of a single small plastic rod that is effective for 3 years and has lower risk with insertion. 119 Although an effective contraceptive method, the intrauterine device may not be considered an appropriate first choice for adolescents, primarily because of the risk of sexually transmitted disease. 120,121 With proper counseling, however, this may be a viable method in selected patients.…”

Section: Sable Et Al Best Transition Practices For Adolescents With Chdmentioning

confidence: 99%

Best Practices in Managing Transition to Adulthood for Adolescents With Congenital Heart Disease: The Transition Process and Medical and Psychosocial Issues

Sable¹,

Foster²,

Uzark³

et al. 2011

Circulation

393

280

View full text Add to dashboard Cite

“…Norplant production was temporarily suspended due to reported increase in failure rates from specific lots [25], but is still available on a limited basis. Etonogestrel (Implanon) provides contraceptive protection for up to 3 years and is a single synthetic rod containing 68 mg of etonogestrel, an active metabolite of desogestrel [26]. Implanon, which is available in the United Kingdom and other European countries and is soon expected to be available in the United States, has been associated with irregular menstrual bleeding and amenorrhea [26].…”

Section: Implantable Contraceptivementioning

confidence: 99%